We thank Drs Pfefferkorn and Rosenberg for their enlightening paper 1 on matrix metalloproteinases (MMPs) after ischemic stroke.
Rats were weighed, neurologically examined according to, 25 and underwent in vivo magnet resonance imaging 24 hours, 2 days, and 8 days after surgery. Measurements were performed on a 1.5T MR scanner (Magnetom Symphony, Siemens). A T2-weighted turbo spin-echo sequence and a heavily T1-weighted inversion recovery sequence were applied in the axial and coronal orientations. Lesion volumes were determined from printed MR images. Midline shift was expressed as ratios of ischemic and nonischemic hemisphere diameters at the bottom of the 3rd ventricle.
Results revealed no differences in physiological parameters. Plasma concentrations of MMP-2/MMP-9 inhibitor I are displayed in the Table. There were no significant differences in lesion volumes, midline shift, body weight, and neurological examination between inhibitor-treated animals and controls.
In conclusion, broad-spectrum MMP inhibitors have been repeatedly reported to have beneficial effects after cerebral ischemia. In our study, an MMP-2/MMP-9 inhibitor failed to influence the effects of transient focal cerebral ischemia. Neither a pharmacodynamic nor a pharmacokinetic malfunction of this inhibitor can be ruled out. Nevertheless, these data, together with the present literature, suggest that therapeutic success due to synthetic MMP inhibitors may possibly not be attributed exclusively to its effects on MMP-2 and MMP-9. This hypothesis concurs with the finding of Pfefferkorn and Rosenberg that BB-94 reduced BBB opening without influencing zymographically determined MMP-2 and MMP-9 levels. 1 Since broadspectrum MMP inhibitors affect other enzymes like TACE as well, the effects on TNF-␣ activity should not be underestimated in the discussion of these drugs. 
Response:
We appreciate the comments of Dr Dittmar and colleagues on the role of selective MMP-2/MMP-9 inhibitors in cerebral ischemia. Most of the inhibitors used in the neurological studies have been broad-spectrum agents such as the one that we used. 1 The finding that an MMP-2/MMP-9 inhibitor failed to affect the endpoints they tested suggests that other MMPs or possibly tumor necrosis factor-␣ converting enzyme (TACE) are also involved. The emphasis of the earlier studies on MMP-2 and MMP-9 (gelatinase A and B, respectively) was based on the availability of gelatin zymography, a highly sensitive quantitative method to detect gelatinases. 2 It is not surprising to find that selective blockade of MMP-2 and MMP-9 is not sufficient to block ischemic damage since over 20 MMPs have been discovered. 3 Other MMPs implicated in stroke include MMP-3 (stromelysin-1) and MMP-14 (membrane-bound MMP). 4, 5 The current MMP inhibitors, including the one tested by Dittmar and colleagues, are poorly soluble. 6 Little is known about the penetration of these agents into the brain. Because they are poorly soluble, a diluent such as DSMO, which may be neuroprotective by itself, is used. The authors do not specify the diluent used. Another potential drawback of this study is that the selected endpoints did not address the effect on the blood-brain barrier (BBB), which is the major site of action of the MMP inhibitors. It would be interesting to know whether the MMP-2/MMP-9 inhibitor had any effect on the BBB, which may be separate from its effect on lesion size.
Computer-aided drug design has increased the number of selective MMP inhibitors. 7 The challenge will be to compare the ones with promising drug profiles against the broadspectrum inhibitors and other classes of agents that interfere with the expression or action of the MMPs, such as the tetracycline derivatives doxycycline and minocycline. 8 Studies such as that described by Dittmar and colleagues will aid greatly in the selection of optimal agents to control the neuroinflammation associated with MMP expression in stroke.
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